Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:8580075rdf:typepubmed:Citationlld:pubmed
pubmed-article:8580075lifeskim:mentionsumls-concept:C0026769lld:lifeskim
pubmed-article:8580075lifeskim:mentionsumls-concept:C0020792lld:lifeskim
pubmed-article:8580075lifeskim:mentionsumls-concept:C0039194lld:lifeskim
pubmed-article:8580075lifeskim:mentionsumls-concept:C0019770lld:lifeskim
pubmed-article:8580075lifeskim:mentionsumls-concept:C1521761lld:lifeskim
pubmed-article:8580075lifeskim:mentionsumls-concept:C0205369lld:lifeskim
pubmed-article:8580075lifeskim:mentionsumls-concept:C0936012lld:lifeskim
pubmed-article:8580075lifeskim:mentionsumls-concept:C0533932lld:lifeskim
pubmed-article:8580075pubmed:issue11lld:pubmed
pubmed-article:8580075pubmed:dateCreated1996-3-18lld:pubmed
pubmed-article:8580075pubmed:abstractTextMultiple sclerosis (MS) is a putative autoimmune disease that is linked with HLA-DR2,w15. Proteolipid protein (PLP) is a candidate autoantigen in MS, but the disease-associated epitopes have not been determined. Using overlapping and non-overlapping PLP peptides, we have studied the T cell response to the major hydrophilic domain PLP 85-159 in the peripheral blood of MS and healthy subjects (HS). Short-term T cell lines (TCL) were selected against each peptide using microwell plates and the frequency of peptide-specific TCL was estimated. PLP 95-116-specific TCL were most efficiently generated and the frequency was significantly higher in MS compared with HS (P < 0.05). When compared between DR2,w15+ and DR2,w15- MS, TCL frequency to PLP 95-116 was significantly higher in DR2,w15+ MS (P < 0.005) and TCL reactive to the overlapping peptide 105-124 were also increased in DR2,w15+ MS (P < 0.025). Using DR gene-transfected L cells, we could show that the DRB1*1501 product of the DR2 haplotype presents PLP 95-116 to TCL selected against the peptide. These results imply that PLP 95-116 represents a major epitope for the DR2,w15+ MS.lld:pubmed
pubmed-article:8580075pubmed:languageenglld:pubmed
pubmed-article:8580075pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8580075pubmed:citationSubsetIMlld:pubmed
pubmed-article:8580075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8580075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8580075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8580075pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:8580075pubmed:statusMEDLINElld:pubmed
pubmed-article:8580075pubmed:monthNovlld:pubmed
pubmed-article:8580075pubmed:issn0953-8178lld:pubmed
pubmed-article:8580075pubmed:authorpubmed-author:KondoTTlld:pubmed
pubmed-article:8580075pubmed:authorpubmed-author:OhashiTTlld:pubmed
pubmed-article:8580075pubmed:authorpubmed-author:TabiraTTlld:pubmed
pubmed-article:8580075pubmed:authorpubmed-author:YamamuraTTlld:pubmed
pubmed-article:8580075pubmed:authorpubmed-author:KunishitaTTlld:pubmed
pubmed-article:8580075pubmed:authorpubmed-author:InobeJJlld:pubmed
pubmed-article:8580075pubmed:issnTypePrintlld:pubmed
pubmed-article:8580075pubmed:volume7lld:pubmed
pubmed-article:8580075pubmed:ownerNLMlld:pubmed
pubmed-article:8580075pubmed:authorsCompleteYlld:pubmed
pubmed-article:8580075pubmed:pagination1771-8lld:pubmed
pubmed-article:8580075pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:meshHeadingpubmed-meshheading:8580075-...lld:pubmed
pubmed-article:8580075pubmed:year1995lld:pubmed
pubmed-article:8580075pubmed:articleTitleAnalysis of proteolipid protein (PLP)-specific T cells in multiple sclerosis: identification of PLP 95-116 as an HLA-DR2,w15-associated determinant.lld:pubmed
pubmed-article:8580075pubmed:affiliationDepartment of Demyelinating Disease and Aging, National Institute of Neuroscience, Tokyo, Japan.lld:pubmed
pubmed-article:8580075pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:8580075pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8580075lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8580075lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8580075lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8580075lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:8580075lld:pubmed